INSULET CORP — Director's Dealing 2016

Mar 11, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INSULET CORP (PODD)
CIK: 0001145197
Period of Report: 2016-03-09

Reporting Person: LEVANGIE DANIEL J (President, Drug Delivery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-09	Common Stock	M	15545	$15.14	Acquired	25358	Direct
2016-03-09	Common Stock	S	7600	$31.04	Disposed	17758	Direct
2016-03-10	Common Stock	M	9455	$15.14	Acquired	27213	Direct
2016-03-10	Common Stock	S	4699	$30.65	Disposed	22514	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-09	Stock Option (Right to Buy)	$15.14	M	15545	Disposed	2021-11-01	Common Stock (15545)	Direct
2016-03-10	Stock Option (Right to Buy)	$15.14	M	9455	Disposed	2021-11-01	Common Stock (9455)	Direct

Footnotes

F1: Includes 1,000 restricted stock units granted on June 3, 2013, which vest on April 30, 2016; 2,000 restricted stock units granted on June 2, 2014, which vest one-half of the total units on April 30, 2016 and one-half of the total units on April 30, 2017; and 6,813 performance share units granted on April 1, 2015, which vest one-third of the total performance share units on April 1, 2016, one-third of the total performance share units on April 1, 2017 and one-third of the performance share units on April 1, 2018, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.

F2: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $31.00 to $31.46. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $30.12 to $31.00. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F4: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant.